Evolution of clinical trial design in early drug development: Systematic review of expansion cohort use in single-agent phase i cancer trials

Journal of Clinical Oncology

Volumn 31, Issue 33, 2013, Pages 4260-4267

  Manji, Arif ^a,c,d   Brana, Irene ^a   Amir, Eitan ^a   Tomlinson, George ^b   Tannock, Ian F ^a   Bedard, Philippe L ^a   Oza, Amit ^a   Siu, Lillian L ^a   Abdul Razak, Albiruni R ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d SOUTHLAKE REGIONAL HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; COHORT ANALYSIS; DATA EXTRACTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REPRODUCIBILITY; STATISTICAL SIGNIFICANCE; STUDY DESIGN; SYSTEMATIC REVIEW; DOSE RESPONSE; METHODOLOGY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; REVIEW; STANDARD; STATISTICAL MODEL; STATISTICS; PROCEDURES; STANDARDS; STATISTICS AND NUMERICAL DATA; TRENDS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); RESEARCH DESIGN;

EID: 84892899816     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.4957     Document Type: Article

References (160)

1. Eisenhauer EA, O'Dwyer PJ, Christian M, et al: Phase I clinical trial design in cancer drug development. J Clin Oncol 18:684-692, 2000 (Pubitemid 30078550)
2. Horstmann E, McCabe MS, Grochow L, et al: Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 352:895-904, 2005 (Pubitemid 40300298)
3. Dent SF, Eisenhauer EA: Phase I trial design: Are new methodologies being put into practice? Ann Oncol 7:561-566, 1996 (Pubitemid 26285634)
4. Sheskin D: Handbook of Parametric and Nonparametric Statistical Procedures. Boca Raton, FL, Chapman & Hall/CRC, 2004
5. Adjei AA, Cohen RB, Franklin W, et al: Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 26:2139-2146, 2008
6. Advani A, Coiffier B, Czuczman MS, et al: Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: Results of a phase I study. J Clin Oncol 28:2085-2093, 2010
7. Ansell SM, Horwitz SM, Engert A, et al: Phase I/II study of an anti-CD30 monoclonal antibody (MDX- 060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 25:2764-2769, 2007 (Pubitemid 47123185)
8. Appels NM, Bolijn MJ, Chan K, et al: Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer. Br J Cancer 98:1951-1958, 2008 (Pubitemid 351821567)
9. Attard G, Reid AH, Yap TA, et al: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26:4563-4571, 2008
10. Azzoli CG, Patel JD, Krug LM, et al: Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: Safety and efficacy in a phase 1 trial. J Thorac Oncol 6:1915-1922, 2011
11. Banerji U, Camidge DR, Verheul HM, et al: The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): A phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res 16:1613-1623, 2010
12. Basche M, Gustafson DL, Holden SN, et al: A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res 12:5471-5480, 2006 (Pubitemid 44497263)
13. Baselga J, Cervantes A, Martinelli E, et al: Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors. Clin Cancer Res 16:4876-4883, 2010
14. Bastholt L, Specht L, Jensen K, et al: Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck. Radiother Oncol 85:24-28, 2007 (Pubitemid 47562580)
15. Batist G, Gelmon KA, Chi KN, et al: Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin Cancer Res 15:692-700, 2009
16. Benson C, White J, De Bono J, et al: A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 96:29-37, 2007 (Pubitemid 46094635)
17. Blum W, Klisovic RB, Becker H, et al: Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol 28:4919-4925, 2010
18. Blum W, Phelps MA, Klisovic RB, et al: Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias. Haematologica 95:1098- 1105, 2010
19. Borthakur G, Kantarjian H, Ravandi F, et al: Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica 96:62- 68, 2011
20. Boss DS, Witteveen PO, van der Sar J, et al: Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Ann Oncol 22:431-437, 2011
21. Brahmer JR, Drake CG, Wollner I, et al: Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:3167-3175, 2010
22. Bratt O, Häggman M, Ahlgren G, et al: Openlabel, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer. Br J Cancer 101:1233-1240, 2009
23. Bröker LE, de Vos FY, van Groeningen CJ, et al: Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity. Clin Cancer Res 12:1760-1767, 2006
24. Bröker LE, Veltkamp SA, Heath EI, et al: A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS- 275183. Clin Cancer Res 13:3906-3912, 2007 (Pubitemid 47037598)
25. Buckner JC, Forouzesh B, Erlichman C, et al: Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer. Invest New Drugs 28:334-342, 2010
26. Burris HA 3rd, Rosen LS, Rocha-Lima CM, et al: Phase 1 experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinoma. Clin Cancer Res 16:1673-1681, 2010
27. Burris HA 3rd, Taylor CW, Jones SF, et al: A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clin Cancer Res 15:6702-6708, 2009
28. Camacho LH, Antonia S, Sosman J, et al: Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 27:1075-1081, 2009
29. Camidge DR, Herbst RS, Gordon MS, et al: A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res 16:1256-1263, 2010
30. Carducci MA, Musib L, Kies MS, et al: Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 24: 4092-4099, 2006 (Pubitemid 46622284)
31. Carr BI, Wang Z, Wang M, et al: Differential effects of vitamin K1 on AFP and DCP levels in patients with unresectable HCC and in HCC cell lines. Dig Dis Sci 56:1876-1883, 2011
32. Castaneda C, Meadows KL, Truax R, et al: Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors. Cancer Chemother Pharmacol 67:455-463, 2011
33. Chawla SP, Chua VS, Fernandez L, et al: Phase I/II and phase II studies of targeted gene delivery in vivo: Intravenous Rexin-G for chemotherapy- resistant sarcoma and osteosarcoma. Mol Ther 17:1651-1657, 2009
34. Comin-Anduix B, Lee Y, Jalil J, et al: Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med 6:22, 2008
35. Cortes JE, Kantarjian HM, Brümmendorf TH, et al: Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 118:4567-4576, 2011
36. de Bono JS, Kristeleit R, Tolcher A, et al: Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors. Clin Cancer Res 14:6663-6673, 2008
37. Demetri GD, Heinrich MC, Fletcher JA, et al: Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res 15:5902-5909, 2009
38. Diamond JR, Bastos BR, Hansen RJ, et al: Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 17:849-860, 2011
39. Drevs J, Medinger M, Mross K, et al: A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer. Anticancer Res 30:2335-2339, 2010
40. Drevs J, Siegert P, Medinger M, et al: Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 25:3045- 3054, 2007 (Pubitemid 47218051)
41. Dumez H, Awada A, Piccart M, et al: A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours. Ann Oncol 17:1158-1165, 2006 (Pubitemid 43985254)
42. Eder JP, Shapiro GI, Appleman LJ, et al: A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res 16:3507-3516, 2010
43. Erlichman C, Hidalgo M, Boni JP, et al: Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol 24:2252-2260, 2006 (Pubitemid 46630654)
44. Eskens FA, de Jonge MJ, Bhargava P, et al: Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-weekoff schedule in patients with advanced solid tumors. Clin Cancer Res 17:7156-7163, 2011
45. Eskens FA, Mom CH, Planting AS, et al: A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer 98:80-85, 2008
46. Eskens FA, Steeghs N, Verweij J, et al: Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors. J Clin Oncol 27:4169-4176, 2009
47. Faivre S, Delbaldo C, Vera K, et al: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35, 2006 (Pubitemid 46630490)
48. Feldman EJ, Lancet JE, Kolitz JE, et al: First-in-man study of CPX-351: A liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol 29:979- 985, 2011
49. Fiedler W, Giaccone G, Lasch P, et al: Phase I trial of SU14813 in patients with advanced solid malignancies. Ann Oncol 22:195-201, 2011
50. Fiedler W, Mesters R, Heuser M, et al: An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia. Leuk Res 34:196-202, 2010
51. Fishman MN, Thompson JA, Pennock GK, et al: Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/ HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res 17:7765-7775, 2011
52. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819, 2010
53. Fong PC, Boss DS, Yap TA, et al: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123-134, 2009
54. Forero-Torres A, Shah J, Wood T, et al: Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer Biother Radiopharm 25:13- 19, 2010
55. Freeman AI, Zakay-Rones Z, Gomori JM, et al: Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 13:221-228, 2006 (Pubitemid 41763501)
56. Friedberg JW, Sharman J, Sweetenham J, et al: Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115:2578- 2585, 2010
57. Fu S, Naing A, Moulder SL, et al: Phase I trial of hepatic arterial infusion of nanoparticle albuminbound paclitaxel: Toxicity, pharmacokinetics, and activity. Mol Cancer Ther 10:1300-1307, 2011
58. Fujisaka Y, Yamada Y, Yamamoto N, et al: Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 66:935-943, 2010
59. Furuse J, Okusaka T, Kaneko S, et al: Phase I/II study of the pharmacokinetics, safety and efficacy of S-1 in patients with advanced hepatocellular carcinoma. Cancer Sci 101:2606-2611, 2010
60. Gojo I, Jiemjit A, Trepel JB, et al: Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 109:2781-2790, 2007 (Pubitemid 46482071)
61. Gordon MS, Sweeney CS, Mendelson DS, et al: Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-inhuman study of patients with advanced solid tumors. Clin Cancer Res 16:699-710, 2010
62. Goss G, Siu LL, Gauthier I, et al: A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group. Cancer Chemother Pharmacol 58:703-710, 2006 (Pubitemid 44167397)
63. Haluska P, Shaw HM, Batzel GN, et al: Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 13:5834-5840, 2007 (Pubitemid 47583908)
64. Haluska P, Worden F, Olmos D, et al: Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol 65:765-773, 2010
65. Hayes TG, Falchook GS, Varadhachary A: Phase IB trial of oral talactoferrin in the treatment of patients with metastatic solid tumors. Invest New Drugs 28:156-162, 2010
66. Herbst RS, Eckhardt SG, Kurzrock R, et al: Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 28:2839-2846, 2010
67. Herbst RS, Hong D, Chap L, et al: Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 27:3557-3565, 2009
68. Herbst RS, Kurzrock R, Hong DS, et al: A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res 16:5883-5891, 2010
69. Higano CS, Corman JM, Smith DC, et al: Phase 1/2 dose-escalation study of a GM-CSFsecreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 113:975-984, 2008
70. Higginbotham KB, Lozano R, Brown T, et al: A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 134:1325-1335, 2008
71. Ho C, Sangha R, Beckett L, et al: Escalating weekly doses of cetuximab and correlation with skin toxicity: A phase I study. Invest New Drugs 29:680- 687, 2011
72. Hofheinz RD, Al-Batran SE, Hochhaus A, et al: An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors. Clin Cancer Res 16:4666-4674, 2010
73. Holen KD, Belani CP, Wilding G, et al: A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose. Cancer Chemother Pharmacol 67: 447-454, 2011
74. Hong DS, Kurzrock R, Oh Y, et al: A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res 17:6582-6591, 2011
75. Hurwitz HI, Dowlati A, Saini S, et al: Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 15:4220-4227, 2009
76. Inaba Y, Arai Y, Yamaura H, et al: Phase I/II study of hepatic arterial infusion chemotherapy with gemcitabine in patients with unresectable intrahepatic cholangiocarcinoma (JIVROSG-0301). Am J Clin Oncol 34:58-62, 2011
77. Iwamoto FM, Lamborn KR, Kuhn JG, et al: A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro-Oncology 13:509-516, 2011
78. Janjigian YY, Lee W, Kris MG, et al: A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors. Cancer Chemother Pharmacol 65:833-838, 2010
79. Jänne PA, Boss DS, Camidge DR, et al: Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res 17:1131-1139, 2011
80. Johannsen M, Spitaleri G, Curigliano G, et al: The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer 46:2926-2935, 2010
81. Jonker DJ, Rosen LS, Sawyer MB, et al: A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. Ann Oncol 22:1413- 1419, 2011
82. Kanai F, Yoshida H, Tateishi R, et al: A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 67:315-324, 2011
83. Kantarjian H, le Coutre P, Cortes J, et al: Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. Cancer 116:2665-2672, 2010
84. Keedy V, Wang W, Schiller J, et al: Phase I study of adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioloalveolar cell lung carcinoma: ECOG 6597. J Clin Oncol 26:4166- 4171, 2008
85. Kim KB, Chesney J, Robinson D, et al: Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clin Cancer Res 17:7451- 7461, 2011
86. Kirschbaum MH, Synold T, Stein AS, et al: A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia. Leukemia 25:1543- 1547, 2011
87. Krop IE, Beeram M, Modi S, et al: Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 28:2698-2704, 2010
88. Kummar S, Gutierrez ME, Gardner ER, et al: Phase I trial of 17-dimethylaminoethylamino-17- demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer 46:340-347, 2010
89. Kurzrock R, Patnaik A, Aisner J, et al: A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res 16:2458-2465, 2010
90. Kurzrock R, Sherman SI, Ball DW, et al: Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 29:2660-2666, 2011
91. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010
92. Langkjer ST, Ejlertsen B, Mouridsen H, et al: Vinorelbine as first-line or second-line therapy for advanced breast cancer: A Phase I-II trial by the Danish Breast Cancer Co-operative Group. Acta Oncol 47:735-739, 2008 (Pubitemid 351878438)
93. Li J, Zhao X, Chen L, et al: Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer 10:529, 2010
94. Lin TS, Stock W, Xu H, et al: A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Leuk Lymphoma 50:1958-1963, 2009
95. LoRusso PM, Rudin CM, Reddy JC, et al: Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 17:2502-2511, 2011
96. Louis CU, Straathof K, Bollard CM, et al: Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother 33:983-990, 2010
97. Löwenberg B, Morgan G, Ossenkoppele GJ, et al: Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia. J Clin Oncol 28:4333-4338, 2010
98. Löwenberg B, Muus P, Ossenkoppele G, et al: Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood 118:6030-6036, 2011
99. Margolin K, Atkins MB, Dutcher JP, et al: Phase I trial of BAY 50-4798, an interleukin-2- specific agonist in advanced melanoma and renal cancer. Clin Cancer Res 13:3312-3319, 2007 (Pubitemid 46944917)
100. Mesa RA, Pardanani AD, Hussein K, et al: Phase1/-2 study of Pomalidomide in myelofibrosis. Am J Hematol 85:129-130, 2010
101. Milton DT, Azzoli CG, Heelan RT, et al: A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. Cancer 107:1034-1041, 2006 (Pubitemid 44291152)
102. Mita MM, Spear MA, Yee LK, et al: Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas. Clin Cancer Res 16:5892-5899, 2010
103. Mross K, Frost A, Steinbild S, et al: Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 26:5511- 5517, 2008
104. Munster PN, Britten CD, Mita M, et al: First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors. Clin Cancer Res 13:1238-1245, 2007 (Pubitemid 46424065)
105. Nabhan C, Davis N, Bitran JD, et al: Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximabrefractory patients. Cancer 117:1490-1497, 2011
106. O'Donnell A, Faivre S, Burris HA 3rd, et al: Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26:1588-1595, 2008
107. Ogawa Y, Tobinai K, Ogura M, et al: Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma. Cancer Sci 99:140-144, 2008 (Pubitemid 350239042)
108. Olmos D, Postel-Vinay S, Molife LR, et al: Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: A phase 1 expansion cohort study. Lancet Oncol 11: 129-135, 2010
109. Paz-Ares LG, Gomez-Roca C, Delord JP, et al: Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol 29:3783-3790, 2011
110. Peereboom DM, Supko JG, Carson KA, et al: A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas. J Neurooncol 100:261-268, 2010
111. [Erratum: J Neurooncol 100:269, 2010]
112. Phuphanich S, Carson KA, Grossman SA, et al: Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma. Neuro-Oncology 10:617-623, 2008
113. Phuphanich S, Supko JG, Carson KA, et al: Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. J Neurooncol 100:95- 103, 2010
114. Pignata S, Amant F, Scambia G, et al: A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy. Cancer Chemother Pharmacol 68:1347-1353, 2011
115. Plummer R, Attard G, Pacey S, et al: Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 13: 6187-6194, 2007 (Pubitemid 350075080)
116. Plummer R, Vidal L, Griffin M, et al: Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors. Clin Cancer Res 15:3177-3183, 2009
117. Quintas-Cardama A, Kantarjian H, Garcia-Manero G, et al: Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 109:248-255, 2007 (Pubitemid 46106239)
118. [Erratum: Cancer 109:2625, 2007]
119. Rizvi NA, Riely GJ, Azzoli CG, et al: Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J Clin Oncol 26:639-643, 2008 (Pubitemid 351264360)
120. Rosen LS, Senzer N, Mekhail T, et al: A phase I dose-escalation study of tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res 17:7754-7764, 2011
121. Rossi JF, Négrier S, James ND, et al: A phase I/II study of siltuximab (CNTO 328), an antiinterleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer 103:1154-1162, 2010
122. Sakamaki H, Ishizawa K, Taniwaki M, et al: Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. Int J Hematol 89:332-341, 2009
123. Schelman WR, Liu G, Wilding G, et al: A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer. Invest New Drugs 29:118-125, 2011
124. Scher HI, Beer TM, Higano CS, et al: Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study. Lancet 375: 1437-1446, 2010
125. Schöffski P, Jones SF, Dumez H, et al: Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours. Eur J Cancer 47:2256-2264, 2011
126. Schwartz GK, LoRusso PM, Dickson MA, et al: Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer 104:1862-1868, 2011
127. Scott L, Soepenberg O, Verweij J, et al: A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours. Ann Oncol 18:569-575, 2007 (Pubitemid 46359641)
128. Sessa C, Perotti A, Lladò A, et al: Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule. Ann Oncol 18:1548-1553, 2007 (Pubitemid 47365489)
129. Shirao K, Nishida T, Doi T, et al: Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate. Invest New Drugs 28:866-875, 2010
130. Simon GR, Ilaria RL Jr, Sovak MA, et al: A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors. Cancer Chemother Pharmacol 68:1233-1241, 2011
131. Slingluff CL Jr, Petroni GR, Olson W, et al: Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol 26:4973-4980, 2008
132. Steele NL, Plumb JA, Vidal L, et al: A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 14:804-810, 2008 (Pubitemid 351231163)
133. Tabernero J, Dirix L, Schöffski P, et al: A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors. Clin Cancer Res 17:6313-6321, 2011
134. Thiessen B, Stewart C, Tsao M, et al: A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: Clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol 65:353-361, 2010
135. Thompson JA, Curti BD, Redman BG, et al: Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol 26:2034-2039, 2008
136. Thompson JA, Kuzel T, Drucker BJ, et al: Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: An open-label, multicenter phase I/II study. Clin Genitourin Cancer 7:E58-E65, 2009
137. Tobinai K, Watanabe T, Tanimoto K, et al: Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab. Cancer Sci 100:1344-1350, 2009
138. Tojo A, Usuki K, Urabe A, et al: A phase I/II study of nilotinib in Japanese patients with imatinibresistant or -intolerant Ph CML or relapsed/refractory Ph ALL. Int J Hematol 89:679-688, 2009
139. Tolcher AW, Mita A, Lewis LD, et al: Phase I and pharmacokinetic study of YM155, a smallmolecule inhibitor of survivin. J Clin Oncol 26:5198-5203, 2008
140. Tolcher AW, Sarantopoulos J, Patnaik A, et al: Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 27:5800-5807, 2009
141. Undevia SD, Innocenti F, Ramirez J, et al: A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(-)XK469 in patients with advanced solid tumours. Eur J Cancer 44:1684-1692, 2008
142. Verstovsek S, Kantarjian H, Mesa RA, et al: Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363:1117-1127, 2010
143. Von Hoff DD, LoRusso PM, Rudin CM, et al: Inhibition of the hedgehog
144. Wakelee HA, Patnaik A, Sikic BI, et al: Phase I and pharmacokinetic study of lexatumumab (HGSETR2) given every 2 weeks in patients with advanced solid tumors. Ann Oncol 21:376-381, 2010
145. Weber JS, O'Day S, Urba W, et al: Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 26:5950-5956, 2008
146. Weiss GJ, Infante JR, Chiorean EG, et al: Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clin Cancer Res 17:2997-3004, 2011
147. Wen PY, Yung WK, Lamborn KR, et al: Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 12:4899-4907, 2006 (Pubitemid 44338577)
148. Wong CI, Koh TS, Soo R, et al: Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol 27:4718-4726, 2009
149. Wong KK, Fracasso PM, Bukowski RM, et al: A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 15:2552-2558, 2009
150. Yap TA, Olmos D, Brunetto AT, et al: Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 29:1271-1279, 2011
151. Yap TA, Vidal L, Adam J, et al: Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 28:3965-3972, 2010
152. Yap TA, Yan L, Patnaik A, et al: First-in-man clinical trial of the oral pan-AKT inhibitor MK-206 in patients with advanced solid tumors. J Clin Oncol 29:4688-4695, 2011
153. Yau T, Chen PJ, Chan P, et al: Phase I dose-finding study of pazopanib in hepatocellular carcinoma: Evaluation of early efficacy, pharmacokinetics, and pharmacodynamics. Clin Cancer Res 17:6914-6923, 2011
154. Yee KW, Zeng Z, Konopleva M, et al: Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 12:5165-5173, 2006 (Pubitemid 44453345)
155. Yong WP, Goh BC, Soo RA, et al: Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies. Ann Oncol 22:2516-2522, 2011
156. Younes A, Bartlett NL, Leonard JP, et al: Brentuximab vedotin (SGN-35) for relapsed CD30- positive lymphomas. N Engl J Med 363:1812-1821, 2010
157. Younes A, Vose JM, Zelenetz AD, et al: A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. Br J Cancer 103:1783-1787, 2010
158. Zhang L, Li S, Zhang Y, et al: Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: An open-label, phase I, rising multiple-dose study. Clin Ther 33:315-327, 2011
159. Zhu AX, Abrams TA, Miksad R, et al: Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer 117:5094-5102, 2011
160. Allegro S, Pond GR, Hotte SJ: The unclear zone in phase II clinical trials. Eur J Cancer 46:2408-2413, 2010